The Editor's Roundtable: Diabetes Mellitus and Coronary Heart Disease

American Journal of Cardiology

Volumn 98, Issue 6, 2006, Pages 842-856

  Friedewald, Vincent E ^a   Leiter, Lawrence A ^b   McGuire, Darren K ^c   Nesto, Richard W ^d   Roberts, William C ^e  

^a UNIVERSITY OF TEXAS   (United States)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ATENOLOL; INSULIN; METFORMIN; SULFONYLUREA;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; HUMAN; HYPERTENSION; INCIDENCE; ISCHEMIC HEART DISEASE; MEDICAL EDUCATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION; TREATMENT OUTCOME; UNITED STATES;

EID: 33748186623     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.06.008     Document Type: Note

References (71)

1. Merz C.N.B., Buse J.B., Tuncer D., and Twillman G.B. Physician attitudes and practices and patient awareness of the cardiovascular complications of diabetes. J Am Coll Cardiol 40 (2002) 1877-1881
2. Coutinho M., Gerstein H.C., Wang Y., and Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 22 2 (1999) 233-240
3. Nathan D.M., Cleary P.A., Backlund J.Y., Genuth S.M., Lachin J.M., Orchard T.J., Raskin P., Zinman B., and Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353 25 (2005) 2643-2653
4. Hudson B.I., Harja E., Moser B., and Schmidt A.M. Soluble levels of receptor for advanced glycation endproducts (sRAGE) and coronary artery disease: the next C-reactive protein?. Arterioscler Thromb Vasc Biol 25 (2005) 879-882
5. Park L., Raman K.G., Lee K.J., Lu Y., Ferran Jr. L.J., Chow W.S., Stern D., and Schmidt A.M. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 4 (1998) 1025-1031
6. Cipollone F., Iezzi A., Fazia M., Zucchelli M., Pini B., Currurullo C., Cesare D.O., Blasis G.D., Muraro R., and Bei R. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 108 (2003) 1070-1077
7. Schmidt A.M., and Stern D.M. RAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes. Trends Endocrinol Metab 11 (2000) 368-375
8. Marx N., Walcher D., Raichle C., Aleksic M., Bach H., Grüb H., Hombach V., Libby P., Zieske A., Homma S., and Strong J. C-peptide colocalizes with macrophages in early arteriosclerotic lesions of diabetic subjects and induces monocyte chemotaxis in vitro. Arterioscler Thromb Vasc Biol 24 (2004) 540-545
9. Walcher D., Aleksic M., Jerg V., Hombach V., Zieske A., Homma S., Strong J., and Marx N. C-peptide induces chemotaxis of human CD4-positive cells: involvement of pertussis toxin-sensitive G-proteins and phosphoinositide 3-kinase. Diabetes 53 (2004) 1664-1670
10. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat?. Diabetes 54 1 (2005) 1-7
11. Unger R.H. Lipotoxic diseases. Annu Rev Med 53 (2002) 319-336
12. Unger R.H., and Orci L. Diseases of liporegulation: new perspective on obesity and related disorders. FASEB J 15 (2001) 312-321
13. Unger R.H., and Orci L. Lipoapoptosis: its mechanism and its diseases. Biochim Biophys Acta 1585 (2002) 202-212
14. McGarry J.D. Banting lecture 2001: Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 51 (2002) 7-18
15. Creager M.A., and Lüscher T.F. Diabetes and vascular disease. Pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 108 (2003) 1527-1532
16. Crall F.V., and Roberts W.C. The extramural and intramural coronary arteries in juvenile diabetes mellitus. Am J Cardiol 64 (1978) 221-230
17. Waller B.F., Palumbo P.J., Lie J.T., and Roberts W.C. Status of the coronary arteries at necropsy in diabetes mellitus with onset after age 30 years. Am J Med 69 (1980) 498-506
18. Das S.R., Vaeth P.A.C., Stanek H.G., de Lemos J.A., Dobbins R.L., and McGuire D.K. Under-diagnosis, increased coronary calcium and sub-optimal cardiovascular risk modification associated with diabetes mellitus in Dallas County: observations from the Dallas Heart Study. Am Heart J 151 (2006) 1087-1093
19. Raggi P., Shaw L.J., Berman D.S., and Callister T.Q. Prognostic value of coronary artery calcium screening in subjects with and without diabetes. J Am Coll Cardiol 43 (2004) 1663-1669
20. Olson J.C., Edmundowicz D., Becker D.J., Kuller L.H., and Orchard T.J. Coronary calcium in adults with type I diabetes: a stronger correlate of clinical coronary artery disease in men than in women. Diabetes 49 (2000) 1571-1578
21. Cipollone F. COX-2 and prostaglandins in atherosclerosis. Lupus 14 (2005) 756-759
22. Cipollone F., Rocca B., and Patrono C. Cyclooxygenase-2 expression and inhibition in atherothrombosis. Arterioscler Thromb Vasc Biol 24 (2004) 246-255
23. Zuccollo A., Shi C., Mastroianni R., Maitland-Tooland K.A., Weistrob R.M., Zang M., Yu S., Jiang B., Oliver-Kranski J.M., Cyatte A.J., and Corda S. The thromboxane A2 receptor antagonist S18886 prevents enhanced atherogenesis caused by diabetes mellitus. Circulation 112 (2005) 3001-3008
24. Steiner G., and Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomized study. Lancet 357 (2001) 905-910
25. Chung E.H., Curran P.J., Sivasankaran S., Chauhan M.S., Pyne C.T., Piemonte T.C., Gossman D.E., Waters J., Bilazarian S., Raby K., Riskala N., Shoraki A., and Nesto R.W. Prevalence of metabolic syndrome in patients <45 years old with acute coronary syndrome presenting for emergent primary percutaneous intervention. J Am Coll Cardiol 47 4 (2006) 216A (Presented at ACC Annual Scientific Session 2006, Atlanta).
26. Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., and Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339 (1998) 229-234
27. NCEP Expert Panel. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA 285 (2001) 2486-2497
28. Evans J., Wang J., and Morris A. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. BMJ 321 (2000) 939-942
29. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
30. McGuire D.K., Emanuelsson H., Granger C.B., Ohman E.M., Moliterno D.J., White H.D., Ardissino D., Box J.W., Califf R.M., Topol E.J., and GUSTO-IIb Investigators. Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Eur Heart J 21 (2000) 1750-1758
31. McGuire D.K., Newby L.K., Bhapkar M.V., Moliterno D.J., Hochman J.S., Klein W., Weaver W.D., Pfisterer M., Dimas A., Corbalan R., Granger C.B., Van de Werf F., Topol E.J., Califf R.M., and SYMPHONY and 2nd SYMPHONY Investigators. Influence of diabetes mellitus and glycemic control strategies on clinical outcomes after acute coronary syndromes: findings from the SYMPHONY and 2ND SYMPHONY Studies. Am Heart J 147 (2004) 246-252
32. Alexander C.M., Landsman P.B., Teutsch S.M., and Haffner S.M. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 52 (2003) 1210-1214
33. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., Forder P., Pillai A., Davis T., Glasziou P., Drury P., Kesaniemi Y.A., Sullivan D., Hunt D., Colman P., d'Emden M., Whiting M., Ehnholm C., Laakso M., and FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
34. Taubert G., Winkelmann B.R., Schleiffer T., März W., Winkler R., Gök R., Klein B., Schneider S., and Boehm B.O. Prevalence, predictors, and consequences of unrecognized diabetes mellitus in 3266 patients scheduled for coronary angiography. Am Heart J 145 (2003) 285-291
35. Saydah S.H., Loria C.M., Eberhardt M.S., and Brancati F.L. Subclinical states of glucose intolerance and risk of death in the U.S. Diabetes Care 24 (2001) 447-453
36. Muhlestein J.B., Anderson J.L., Horne B.D., Lavasani F., Maycock C.A.A., Bair T.L., Pearson R.R., Carlquist J.F., and Intermountain Heart Collaborative Study Group. Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention. Am Heart J 146 (2003) 351-358
37. Norhammar A., Tenerz A., Nilsson G., Hamsten A., Efendic S., Rydén L., and Malmberg K. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 359 (2002) 2140-2144
38. American Diabetes Association Standards of Medical Care in Diabetes - 2006. Diabetes Care 29 (2006) S4-S42
39. Beisswenger P., Heine R.J., Leiter L.A., Moses A., and Tuomilehto J. Prandial glucose regulation in the glucose triad: emerging evidence and insights. Endocrine 25 3 (2004) 195-202
40. Turner R., Stratton I., Horton V., Manley S., Zimmet P., Mackay I.R., Shattock M., Bottazzo G.F., and Holman R. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 350 (1997) 1288-1293
41. Malmberg K., DIGAMI (Diabetes Mellitus, and Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ 314 (1997) 1512-1515
42. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. A report of the Am Coll of Cardiol/Am Heart Assoc Task Force on Practice Guidelines (Committee to revise the 1999 guidelines). Bethesda, MD: American College of Cardiology, American Heart Association; 2004. Available at: http://www.guideline.gov/summary/summary.aspx?doc_id=5457&nbr=003734 &string=STEMI. Accessed on May 1, 2006.
43. National Registry of Myocardial Infarctions Investigators, McGuire D.K., Khera A., de Lemos J.A., Peterson E.D., Warner J.J., Parsons L.S., Rogers W.J., and Canto J.G. Women with diabetes mellitus have the greatest reduction in mi mortality over the past decade: evaluation of 1,428,596 patients enrolled in the National Registry of Myocardial Infarction (NRMI) 2, 3, & 4 from 1994-2002. J Am Coll Cardiol 43 suppl 5 (2004) 284A
44. Van den Berghe G., Wouters P., Weekers F., Verwaest C., Bruyninckx F., Schetz M., Vlasselaers D., Ferdinande P., Lauwers P., and Bouillon R. Intensive insulin therapy in critically ill patients. N Engl J Med 345 (2001) 1359-1367
45. Malmberg K., Rydén L., Wedel H., Birkeland K., Bootsma A., Dickstein K., Efendic S., Fisher M., Hamsten A., Herlitz J., Hildebrandt P., MacLeod K., Laasko M., Torp-Pedersen C., Waldenström A., and DIGAMI 2 Investigators. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 26 (2005) 650-661
46. Malmberg K., and McGuire D.K. Diabetes and acute myocardial infarction: the role of insulin therapy. Am Heart J 138 (1999) S381-S386
47. Ceremuzynski L., Budaj A., Czepiel A., Burzykowski T., Achremczyk P., Smielak-Korombel W., Maciejewicz J., Dziubinska J., Nartowicz E., Kawka-Urbanek T., Piotrowski W., Hanzlik J., Cieslinski A., Kawecka-Jaszcz K., Gessek J., and Wrabec K. Low-dose glucose-insulin-potassium is ineffective in acute myocardial infarction: results of a randomized multicenter Pol-GIK trial. Cardiovasc Drugs Ther 13 (1999) 191-200
48. Svensson A.M., McGuire D.K., Abrahamsson P., and Dellborg M. Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. Eur Heart J 26 (2005) 1255-1261
49. Kahn R., Buse J., Ferrannini E., and Stern M. The metabolic syndrome: time for a critical appraisal. Diabetes Care 28 (2005) 2289-2304
50. American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care 28 (2005) S4-S36
51. The Heart Protection Study Investigators. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
52. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A.W., Livingston S.J., Thomason J., Mackness M.I., Charlton-Menys V., and Fuller H. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
53. CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 287 19 (2002) 2542-2551
54. Gaede P., Vedel P., Larsen N., Jensen G.V., Parving H.H., and Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 (2003) 383-393
55. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
56. Grundy S.M., Vega G.L., McGovern M.E., Tulloch B.R., Kendall D.M., Fitz-Patrick D., Ganda O.P., Rosenson R.S., Buse J.B., Robertson D.D., Sheehan J.P., and Diabetes Multicenter Research Group. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 162 14 (2002) 1568-1576
57. Taylor A.J., Sullenberger L.E., Hyun J.L., Lee J.K., and Grace K.A. Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2. Circulation 110 (2004) 3512-3517
58. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317 (1998) 703-713
59. Dickstein K., and Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 360 (2002) 752-760
60. Schnell O., Schafer O., Kleybrink S., Doering W., Standl E., and Otter W. Intensification of therapeutic approaches reduces mortality in diabetic patients with acute myocardial infarction. Diabetes Care 27 (2004) 455-460
61. Abraira C., Colwell J.A., Nuttall F.Q., Sawin C.T., Nagel N.J., Comstock J.P., Emanuele N.V., Levin S.R., Henderson W., and Lee H.S. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care 18 (1995) 1113-1123
62. Prout T.E., Knatterud G.L., Meinert C.L., and Klimt C.R. The UGDP controversy. Clinical trials versus clinical impressions. Diabetes 21 (1972) 1035-1040
63. Misbin R.I. The phantom of lactic acidosis due to metformin in patients with diabetes. Diabetes Care 27 (2004) 1791-1793
64. Inzucchi S.E., Masoudi F.A., Wang Y., Kosiborod M., Foody J.M., Setaro J.F., Havranek E.P., and Krumholz H.M. Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project. Diabetes Care 28 (2005) 1680-1689
65. Masoudi F.A., Inzucchi S.E., Wang Y., Havranek E.P., Foody J.M., and Krumholz H.M. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 111 (2005) 583-590
66. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865
67. Dormandy J.A., Charbonnel B., Eckland D.J.A., and Erdmann E. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
68. Choi D., Kim S.-K., Choi S.-H., Ko Y.-G., Ahn C.-W., Jang Y., Lim S.-K., Lee H.-C., and Cha B.-S. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 27 11 (2004) 2654-2660
69. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., Joyal S.V., Hill K.A., Pfeffer M.A., Skene A.M., and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
70. Woodfield S.L., Lundergan C.F., Reiner J.S., Greenhouse S.W., Thompson M.A., Rohrbeck S.C., Deychak Y., Simoons M.L., Califf R.M., Topol E.J., and Ross A.M. Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol 28 (1996) 1661-1669
71. Norhammar A., Malmberg K., Diderholm E., Lagerqvist B., Lindahl B., Ryden L., and Wallentin L. Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. J Am Coll Cardiol 43 (2004) 585-591